New drugs for the old enemy

As we develop new methods to create more biologically relevant models for research in understanding disease etiology and innovating new treatment options, one of the most requested areas for educational materials is 3D cell models such as organoid and spheroid systems. Thermo Fisher Scientific is proud to present our webinar series on 3D culture & analysis, and more importantly, how you can get started, how to monitor and analyze 3D models and what to do with these once you have successfully cultured your organoid or spheroid model of interest. In this series we will specifically cover the following areas and after taking part in the presentations, hopefully you will be better equipped to answer the basic questions and feel enabled to get started using 3D culture systems.

Single cell cloning (SCC) is a critical and high-value process for an increasing number of applications including cell engineering; stable cell lines for therapeutic mAbs and biosimilars; vector production for gene therapy; and many more. During this webinar, Tom Kelly from Janssen (part of Johnson & Johnson) will talk about his use of Solentim’s VIPS™ (Verified in-situ Plate Seeding) system, the world’s first All-in-One Single Cell Cloning System. He will explain why Janssen moved away from older generation CLD technology using Clonepix, which was based on detecting and picking high-producer clones in semi-solid media.

The clinical development marketplace continues to become more complex and competitive, with stricter regulatory standards and trial oversight—all the while demanding patient-centric drug development. These, and other factors, contribute to unsustainable costs and longer timelines before much-needed therapies reach the market.

In order to ensure the safety of patients, the toxicological risk assessment needs to thoroughly evaluate all potential risks which may be caused by any component present in a pharmaceutical drug product.